Page 41 - ஜான்ஸ் ஹாப்கின்ஸ் பள்ளி ஆஃப் மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Published: Apr 28, 2021   Neuronal viability was preserved, resulting in improved spatial learning and memory   GAITHERSBURG, Md. (BUSINESS WIRE) Neuraly, a clinical stage biotechnology company pioneering disease-modifying agents for neurodegenerative disorders, today announced publication in the peer-reviewed journal Acta Neuropathologica Communications of preclinical data that contributed to the therapeutic rationale for clinical evaluation of NLY01 in Alzheimer’s and Parkinson’s diseases. The research was conducted in collaboration with Dr. Ted Dawson’s lab at the Johns Hopkins School of Medicine. The publication, entitled “Blocking microglial activation of reactive astrocytes is neuroprotective in models of Alzheimer’s disease” demonstrated that NLY01, an engineered exendin-4, glucagon-like peptide-1 receptor (GLP-1R) agonist, can selectively block β-amyloid-induced activation of microglia through upregulated GLP-1R, inhibit formation of reactive astro

Seulki leeViktor roschkeTed dawsonActa neuropathologica communicationsJohns hopkins school of medicineJohns hopkins schoolChief executive officerNature medicineChief scientific officerEuraly announces publication in acta neuropathologica communications of preclinical data detailing the neuroprotective effect nly01 models alzheimers diseaseடெட் டாசன்ஜான்ஸ் ஹாப்கின்ஸ் பள்ளி ஆஃப் மருந்துஜான்ஸ் ஹாப்கின்ஸ் பள்ளிதலைமை நிர்வாகி அதிகாரிஇயற்கை மருந்துதலைமை அறிவியல் அதிகாரி